Neoleukin Therapeutics Investor Relations Material
Latest events
M&A Announcement
Neoleukin Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from over 8,000 public companies
Neoleukin Therapeutics (NCT), a biopharmaceutical company developing immunotherapies for cancer, inflammation and autoimmunity diseases using protein design technology. NCT's lead product candidate is an immunotherapy for non-small cell lung cancer (NSCLC) which relies on novel combination of biologic agents to fight cancer. The company develops protein-based therapies that direct the body's immune system to attack diseased cells. It is developing TLR4 agonists for treatment of inflammatory diseases and cancer, notably Phase III-ready NP1201TLR4.
Latest articles
Webull vs Robinhood: Which Platform Suits You?
In the competitive world of online trading platforms, Webull and Robinhood have emerged as two of the top choices for investors.
24 Nov 2023
Norway's Sovereign Wealth Fund: Transforming Oil Wealth into Lasting Prosperity
But what makes Norway’s striking of oil so fundamentally different from its worse faring counterparts? The answer is in large part its Norwegian Government Pension fund, and Norges Bank Investment Management
24 Nov 2023
Danaher Business System and Acquisition History
Since the early 1990s, Danaher's management team has transformed a group of under-performing industrial manufacturing companies into a global powerhouse in life sciences and diagnostics.
22 Nov 2023
Ticker symbol
NLTX
Country
🇺🇸 United States